Gian Lifecare's Q2 FY25 financials reveal strong growth in PAT and Net Sales, despite 'Sell' call from MarketsMOJO

Gian Lifecare, a microcap company in the hospital and healthcare services industry, has recently announced its financial results for the quarter ending September 2024. The results, declared on November 14, 2024, have received a ‘Sell’ call from MarketsMOJO.

Despite the negative stock call, Gian Lifecare has shown positive financial performance in the second quarter of the fiscal year 2024-2025. The company’s score has fallen from 9 to 6 in the last three months, indicating a slight decline in its overall performance.

However, there are several factors that are working in favor of Gian Lifecare based on its September 2024 financials. The company’s Profit After Tax (PAT) for the nine-month period has grown by a staggering 577.55% year on year, while its Net Sales have also shown a positive growth of 35.83% year on year. Moreover, the PAT trend is very positive, indicating a strong financial performance.

In addition, Gian Lifecare’s PAT for the nine-month period is higher at Rs 2.34 crore compared to the preceding 12-month period ended September 2024, which was Rs 1.06 crore. This shows that the company has already surpassed its sales from the previous year in just nine months.

On the other hand, the company’s Operating Profit (PBDIT) for the quarter is at its lowest in the last five quarters, standing at Rs 0.22 crore. This indicates a negative trend in the near term for the company’s operating profit.

Overall, Gian Lifecare’s financial results for the quarter ending September 2024 show a mix of positive and negative trends. Investors should carefully consider these factors before making any investment decisions.